New approaches to the pharmacological management of generalized anxiety disorder
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Selective serotonin reuptake inhibitors (SSRIs) and serotonine reuptake Inhibitors (SNRIs) together with pregabalin are actually considered by international guidelines as the first-line choice for generalized anxiety disorder (GAD) treatment. However, 50% of GAD patients have poor response to first-line treatments and different molecules, such as atypical antipsychotics and mood stabilizers, have been used for treating this condition. Purpose of the present article is to provide an overview of the most recent pharmacological approaches for the treatment of GAD and the rationale for their use. AREAS COVERED: A research in the main database sources has been conducted to obtain an overview of the new pharmacological approaches in GAD (anticonvulsants, atypical antipsychotics, agomelatine, memantine, ondansetron and riluzole). EXPERT OPINION: Among unlabelled molecules, quetiapine seems to have the most robust evidence of efficacy in GAD. Valproic acid and agomelatine appear to be effective in GAD patients, but the data are preliminary and need to be confirmed by future studies. Quetiapine is a promising molecule for GAD treatment but its use would be complicated by long-term metabolic side effects. Future research will have the objective to find more targeted molecules for the treatment of this disorder in light of its specific etiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235 · cited 1×
“Till date, the most accepted pathophysiological model of GAD asserts that acute symptoms would be the result of neurotransmitter dysregulation and the negative effects of illness in the long-term would be mediated by brain changes and endocrine-immune abnormalities [19].”
BackgroundMonk, C. S., Telzer, E. H., Mogg, K., Bradley, B. P., Mai, X., Louro, H. M. C., Chen, G., McClure-Tone, E. B., Ernst, M., & Pine, D. S. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.5.568 · Cited by 682 · cited 1×
“In GAD patients, this structure seems to be always activated with overstimulation of amygdala neurons and onset of anxious symptoms [38].”
BackgroundEtkin, A., Prater, K. E., Schatzberg, A. F., Menon, V., & Greicius, M. D. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.104 · Cited by 664 · cited 1×
“2 Physiopathology of GAD The imbalance of neurotransmitters in GAD patients is responsible for amygdala hyperactivation resulting in psychic and somatic anxious symptoms [35].”
BackgroundMaher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558 · cited 1×
“antihistamines: risperidone, olanzapine, quetiapine [58].”
de Girolamo, G., Dagani, J., Purcell, R., Cocchi, A., & McGorry, P. D. (2012) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796011000746 · Cited by 544 · cited 1×
“In this sense, primary prevention (identification of subjects at high risk) and secondary prevention (early recognition) strategies can reduce the duration of untreated illness and consequently improve the course of GAD [7].”
BackgroundBeesdo, K., Pine, D. S., Lieb, R., & Wittchen, H.-U. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.177 · Cited by 494 · cited 1×
“Of note, a family history of GAD, behavioral inhibition, childhood separation, parental overprotection and dysfunctional family functioning were all found as risk factors for developing GAD [8].”
BackgroundKessler, R. C., Gruber, M., Hettema, J. M., Hwang, I., Sampson, N., & Yonkers, K. A. (2008) · Psychological Medicine · doi:10.1017/s0033291707002012 · Cited by 493 · cited 1×
“Of note, depressive symptoms usually appear after GAD onset, so that early diagnosis and prescription of an adequate treatment could prevent comorbidity and ameliorate the outcome of GAD patients [6].”
BackgroundBandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., Möller, H.-J., WFSBP Task Force on Mental Disorders in Primary Care, & WFSBP Task Force on Anxiety Disorders, O. A. P. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667114 · Cited by 428
The Role of the Central Nucleus of the Amygdala in Mediating Fear and Anxiety in the Primate
Kalin, N. H., Shelton, S. E., & Davidson, R. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0292-04.2004 · Cited by 406 · cited 1×
“This area receives projections from frontal and prefrontal cortex, activated by serotonergic projections of raphe nuclei and noradrenergic projections of locus coeruleus [36].”
BackgroundThe epidemiology of generalized anxiety disorder
Kessler, R. C., Keller, M. B., & Wittchen, H.-U. (2001) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70204-5 · Cited by 337 · cited 1×
“Generalized anxiety disorder (GAD) is a condition with a 12-month prevalence of 2% in European population [1].”
Background
Cited by
Biological markers of generalized anxiety disorder
Maron, E., & Nutt, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/dnutt · Cited by 164
Fitzgerald, J. M., Phan, K. L., Kennedy, A. E., Shankman, S. A., Langenecker, S. A., & Klumpp, H. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.05.013 · Cited by 68
Agomelatine for the treatment of generalized anxiety disorder
Buoli, M., Grassi, S., Serati, M., & Altamura, A. C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359257 · Cited by 61
Self-citationBiological Markers of Generalized Anxiety Disorder
Maron, E., & Nutt, D. (2018) · Focus · doi:10.1176/appi.focus.16205 · Cited by 42
Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
Levitan, M., Papelbaum, M., & E Nardi, A. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s67470 · Cited by 25
Metadata
- Authors
- Buoli, M., Caldiroli, A., Caletti, E., Paoli, R. A., & Altamura, A. C.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2013-01-03
- Volume
- 14
- Issue
- 2
- Pages
- 175-184
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2117818255
- Cited by
- 40
- References
- 17
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New approaches to the pharmacological management of generalized anxiety disorder. https://app.cochat.ai/papers/10.1517/14656566.2013.759559
- The paper
- Buoli, M., Caldiroli, A., Caletti, E., Paoli, R. A., & Altamura, A. C. (2013). New approaches to the pharmacological management of generalized anxiety disorder. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2013.759559
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.